MedTrace Logo

To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children

NCT02164110 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3632

Last updated 2014-12-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children.

Conditions

  • Prevention Harmful Effects

Interventions

BIOLOGICAL

Euvichol

* Number of doses and intervals: two doses/Weeks 0 and 2 * Method of administration: oral administration * Dose of drug to be administered: 1.5 mL/dose

BIOLOGICAL

Shanchol

* Number of doses and intervals: two doses/Weeks 0 and 2 * Method of administration: oral administration * Dose of drug to be administered: 1.5 mL/dose

Sponsors & Collaborators

  • Instituto Universitario IVI

    collaborator OTHER

  • EuBiologics Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Roberto A. Espos, MD · De La Salle University Hospital Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-09-30
Completion
2014-10-31

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02164110 on ClinicalTrials.gov